Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07123467 · ClinicalTrials.gov registry record · Phase 3
Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
A Phase 3 study of Anxiety Disorders and Generalized Anxiety Disorder (GAD), sponsored by Wayne State University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT07123467 is a Phase 3 study of Anxiety Disorders and Generalized Anxiety Disorder (GAD) that is actively recruiting participants, run by Wayne State University. The registered enrollment target is 90 participants, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07123467, a Phase 3 study of Anxiety Disorders and Generalized Anxiety Disorder (GAD), is actively recruiting participants, sponsored by Wayne State University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with placebo.
Conditions Studied
Interventions
- DRUG Low-Dose Cannabidiol
- DRUG Placebo Matched to Moderate-Dose Cannabidiol
- DRUG Moderate-Dose Cannabidiol
- DRUG Placebo Matched to Low-Dose Cannabidiol
Study Locations (1)
Michigan
- Wayne State University School of Medicine, Tolan Park Medical Building - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07123467
The ClinicalTrials.gov registry entry for NCT07123467 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,139-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (92% lower). The listed sponsor is Wayne State University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 4 interventions - of which Low-Dose Cannabidiol is the first listed.
NCT07123467 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07123467 about?
NCT07123467 is a clinical study titled "Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder". This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cann...
What is the current status of trial NCT07123467?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2025-11-03. Estimated completion is 2027-08-31.
What conditions does trial NCT07123467 study?
This clinical trial studies the following conditions: Anxiety Disorders, Generalized Anxiety Disorder (GAD).
What interventions are being tested in trial NCT07123467?
The interventions under investigation include: Low-Dose Cannabidiol (DRUG), Placebo Matched to Moderate-Dose Cannabidiol (DRUG), Moderate-Dose Cannabidiol (DRUG), Placebo Matched to Low-Dose Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT07123467?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07123467 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fluoxetine vs CBT in Childhood Anxiety Disorders
ACTIVE NOT RECRUITING · Phase 3
-
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS
COMPLETED · Phase 3
-
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
COMPLETED · Phase 3
-
Telephone-Based Care Management Program for Individuals With Anxiety Disorders
COMPLETED · Phase 3
-
School-based Treatment for Anxious Children
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.